News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,948 Results
Type
Article (59603)
Company Profile (124)
Press Release (632209)
Multimedia
Podcasts (222)
Webinars (34)
Section
Business (214648)
Career Advice (2718)
Deals (34277)
Drug Delivery (221)
Drug Development (78796)
Employer Resources (202)
FDA (16989)
Job Trends (13873)
News (325071)
Policy (33650)
Tag
2027 BioCapital Standard (4)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (3)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (10)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (7)
2027 Genetown Elite (3)
2027 Genetown Premier (1)
2027 Genetown Standard (11)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (11)
40 Under 40 (2)
Academia (2597)
Academic (1)
Accelerated approval (73)
ADA (48)
Adcomms (44)
Allergies (215)
Alliances (42540)
ALS (266)
Alzheimer's disease (2028)
Antibody-drug conjugate (ADC) (715)
Approvals (17520)
Artificial intelligence (934)
ASCO (333)
Autoimmune disease (478)
Automation (70)
Bankruptcy (358)
Belgium (36)
Best Places to Work (10319)
BIO (77)
Biologics (85)
BIOSECURE Act (23)
Biosimilars (283)
BioSpace Insights (210)
Biotechnology (81)
Bispecific (44)
Bladder cancer (235)
Brain cancer (93)
Breast cancer (889)
Cancer (7355)
Cardiovascular disease (625)
Career advice (2335)
Career pathing (62)
CAR-T (421)
CDC (82)
CDMO (208)
Celiac Disease (5)
Cell-line development (2)
Cell therapy (1127)
Cervical cancer (62)
Clinical research (70375)
Collaboration (2451)
Commercialization (52)
Company closure (9)
Compensation (1874)
Complete response letters (126)
COVID-19 (2949)
CRISPR (137)
CRO (4)
C-suite (1525)
Cystic fibrosis (172)
Data (10181)
Decentralized trials (4)
Denatured (64)
Depression (216)
Dermatology (183)
Diabetes (775)
Diagnostics (6806)
Digital health (64)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (454)
Drug pricing (247)
Drug shortages (35)
Duchenne muscular dystrophy (372)
Earnings (91313)
Editorial (85)
Employer branding (26)
Employer resources (176)
ESMO (401)
Events (100778)
Executive appointments (1248)
Eye disease (16)
FDA (21838)
Fibrodysplasia Ossificans Progressiva (16)
Fragile X (5)
Friedreich's ataxia (27)
Frontotemporal dementia (40)
Funding (2037)
Gene editing (287)
Generative AI (85)
Gene therapy (900)
GLP-1 (1334)
Government (4956)
Grass and pollen (8)
Guidances (432)
Healthcare (17216)
Hematology (188)
HIV (115)
Huntington's disease (86)
Idiopathic pulmonary fibrosis (14)
IgA nephropathy (151)
Immunology and inflammation (419)
Immuno-oncology (148)
Indications (270)
Infectious disease (3370)
Inflammatory bowel disease (267)
Inflation Reduction Act (15)
Influenza (156)
Intellectual property (359)
Interviews (506)
IPO (16835)
IRA (58)
Job creations (3738)
Job search strategy (1895)
JPM (73)
Kidney cancer (30)
Kidney disease (159)
Labor market (146)
Layoffs (707)
Leadership (67)
Legal (8045)
Licensing (89)
Liver cancer (114)
Longevity (49)
Lung cancer (1011)
Lung diease (22)
Lymphoma (522)
Machine learning (71)
Management (68)
Manufacturing (1449)
Marketing (32)
MASH (242)
Medical affairs (5)
Medical device (12992)
Medtech (13264)
Mergers & acquisitions (18897)
Metabolic disorders (1999)
mRNA (316)
Multiple sclerosis (242)
Multispecific (6)
NASH (24)
Netherlands (32)
Neurodegenerative disease (576)
Neuropsychiatric disorders (145)
Neuroscience (4043)
Neurotech (4)
NextGen: Class of 2026 (5678)
Non-profit (3693)
Now hiring (97)
Obesity (964)
Opinion (386)
Ovarian cancer (285)
Pain (326)
Pancreatic cancer (427)
Parkinson's disease (455)
Partnered (41)
Patents (757)
Patient advocacy (3)
Patient recruitment (932)
Patient selection (94)
Peanut (73)
People (53393)
Peptides (25)
Pharmaceutical (35)
Pharmacy benefit managers (41)
Phase 1 (21363)
Phase 2 (30762)
Phase 3 (24080)
Pipeline (13199)
Policy (415)
Postmarket research (2603)
Preclinical (8779)
Press Release (62)
Prostate cancer (391)
Psychedelics (93)
Radioligand (2)
Radiopharmaceuticals (391)
Rare diseases (1505)
Real estate (5152)
Recruiting (79)
Regenerative medicine (26)
Regulatory (27911)
Reports (96)
Research institute (2390)
Resumes & cover letters (437)
Rett syndrome (58)
RNA editing (37)
RSV (95)
Schizophrenia (216)
Series A (357)
Series B (254)
Service/supplier (10)
Sickle cell disease (135)
Special edition (36)
Spinal muscular atrophy (183)
Sponsored (59)
Startups (3353)
State (1)
Stem cells (6)
Stomach cancer (24)
Substance use disorders (22)
Supply chain (156)
Switzerland (9)
Tariffs (107)
Tax incentives (2)
The Weekly (156)
Vaccines (1381)
Venture capital (171)
Weight loss (651)
Wet AMD (7)
Women's health (167)
Women in leadership (1)
Worklife (28)
Date
Today (116)
Last 7 days (793)
Last 30 days (2976)
Last 365 days (31213)
2026 (26080)
2025 (30307)
2024 (34050)
2023 (38472)
2022 (49480)
2021 (53255)
2020 (50534)
2019 (41444)
2018 (31505)
2017 (32413)
2016 (30966)
2015 (34910)
2014 (29740)
2013 (25614)
2012 (25346)
2011 (25828)
2010 (23923)
Location
Africa (870)
Alabama (98)
Alaska (6)
Arizona (374)
Arkansas (15)
Asia (41573)
Australia (7026)
California (15780)
Canada (3951)
China (1782)
Colorado (655)
Connecticut (715)
Delaware (506)
Europe (97290)
Florida (2426)
Georgia (487)
Hawaii (5)
Idaho (55)
Illinois (1239)
India (126)
Indiana (674)
Iowa (33)
Japan (724)
Kansas (137)
Kentucky (51)
Louisiana (47)
Maine (90)
Maryland (1866)
Massachusetts (11235)
Michigan (391)
Minnesota (813)
Mississippi (6)
Missouri (161)
Montana (24)
Nebraska (25)
Nevada (182)
New Hampshire (77)
New Jersey (4205)
New Mexico (26)
New York (4103)
North Carolina (1981)
North Dakota (10)
Northern California (8153)
Ohio (457)
Oklahoma (26)
Oregon (44)
Pennsylvania (2987)
Puerto Rico (29)
Rhode Island (45)
South America (1204)
South Carolina (101)
South Dakota (2)
Southern California (6323)
Tennessee (249)
Texas (2545)
United States (55050)
Utah (449)
Vermont (1)
Virginia (386)
Washington D.C. (77)
Washington State (1224)
West Virginia (4)
Wisconsin (168)
Wyoming (6)
691,948 Results for "wong s biotech stock report".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
2026 IPO stock tracker: How newly public biotechs are performing
BioSpace
is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
October 28, 2026
·
1 min read
·
Gabrielle Masson
Drug Development
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
August 17, 2026
·
3 min read
·
Gabrielle Masson
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.
October 30, 2026
·
2 min read
·
Gabrielle Masson
IPO
Steady stream of crossover rounds stock biotech’s IPO pipeline
Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.
September 9, 2026
·
7 min read
·
Annalee Armstrong
IPO
Biotech IPOs raise $7.5B as sector’s performance rally flattens
While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same period was muted, with most of the yearly gains for the U.S. biotech-specific index largely driven by the first half of 2026.
October 26, 2026
·
1 min read
·
Gabrielle Masson
Venture capital
Alphabet’s GV is one of biotech’s most influential corporate investors
The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
October 27, 2026
·
2 min read
·
Annalee Armstrong
IPO
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
September 25, 2026
·
2 min read
·
Gabrielle Masson
China
China’s licensing deals soar as US biotechs enjoy a bumper M&A year
China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field.
October 21, 2026
·
3 min read
·
Annalee Armstrong
Rare diseases
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing operational rethink
The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful near-term milestones.
September 3, 2026
·
2 min read
·
Tristan Manalac
China
China’s surging biotech sector represents both competition and lifeline for the US
As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regulation could help the U.S. maintain its edge.
September 23, 2026
·
8 min read
·
Shawna Williams
1 of 69,195
Next
